60 Degrees Pharmaceuticals (SXTP) Projected to Release Quarterly Earnings on Thursday

60 Degrees Pharmaceuticals (NASDAQ:SXTP) is anticipated to issue its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect 60 Degrees Pharmaceuticals to announce earnings of ($0.61) per share and revenue of $0.27 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 20, 2026 at 12:30 PM ET.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.16). The company had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.20 million. On average, analysts expect 60 Degrees Pharmaceuticals to post ($3.31) EPS for the current fiscal year and ($2.14) EPS for the next fiscal year.

60 Degrees Pharmaceuticals Trading Down 4.7%

Shares of 60 Degrees Pharmaceuticals stock opened at $0.52 on Wednesday. The business’s 50 day moving average price is $0.97 and its 200 day moving average price is $1.72. 60 Degrees Pharmaceuticals has a one year low of $0.48 and a one year high of $8.62.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research note on Monday, September 21st. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, 60 Degrees Pharmaceuticals presently has an average rating of “Hold” and an average price target of $13.85.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing medicines for tropical and infectious diseases. The company’s work centers on treatments and preventive therapies for conditions that affect travelers, military personnel and populations in regions where infectious diseases are prevalent. Its lead product is Arakoda (tafenoquine), an oral prescription medicine approved by the U.S. Food and Drug Administration in 2018 for the prevention of malaria in adults.